NCT06438705

99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors

Clinical Application of a Novel 99mTc Labeled Fibroblast Activating Protein (FAP) Targeted Molecular Probe in Early Diagnosis of Tumors

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: Nanjing First Hospital, Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

At present, radiopharmaceuticals targeting FAP have been developed for the diagnosis and treatment of various tumors. Considering the problems of fast tumor tissue clearance and short retention time in small molecule FAP inhibitors based on quinoline rings, this project optimized their ligands and developed a new FAP targeted technetium labeled molecular imaging probe for SPECT/CT imaging research to evaluate its safety in clinical application and its effectiveness in tumor diagnosis.

Conditions

• Head and Neck Tumor
• Lung Cancer
• Pancreatic Cancer

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	SPECT-CT imaging	The subjects were intravenously injected with 99mTc labeled FAPI imaging agent, and drank 300-500ml of water after administration. SPECT-CT imaging was performed 60 minutes later

Timeline

• Start date: 2024-06-01
• Primary completion: 2026-01-31
• Completion: 2026-05-31
• First posted: 2024-06-03
• Last updated: 2025-03-11

Locations

1 site across 1 country: China